Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive immune thrombocytopenia data for Revolade

Novartis reports positive immune thrombocytopenia data for Revolade

19th October 2017

Novartis has announced the publication of new clinical trial data showing the effectiveness of Revolade in the treatment of immune thrombocytopenia (ITP).

Positive safety and efficacy data from the EXTEND study has been published in the medical journal Blood, showing how Revolade can deliver long-term benefits for adults with chronic or persistent ITP.

A majority of patients receiving Revolade for up to 8 years of continuous treatment were able to maintain a substantial clinical response, with many no longer needing concomitant ITP medications.

This data offers further evidence of the long-term safety profile and treatment benefits of Revolade for ITP, a rare and potentially serious blood disorder that interferes with normal blood clotting processes.

Dr Vas Narasimhan, global head of drug development and chief medical officer of Novartis, said: "The EXTEND results reinforce Revolade as a trusted treatment option that can be used over the long-term for those living with this chronic and rare disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.